Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lenny Shultz"'
Autor:
Carlos M. Leon, Zheng Gong, Qing Li, Jiayuan Shi, Wulin Zuo, Muneer G. Hasham, Lenny Shultz, Sheng Li, Guangwen Ren
Publikováno v:
Cancer Research. 82:1863-1863
Chemotherapy has significantly improved the survival of cancer patients. However, the vast variation in treatment responses remains a major issue in the clinic. It is imperative to understand the molecular mechanisms underlying treatment failure in s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86f4defd8b1390d2efa0b68ee4a07777
https://doi.org/10.1158/1538-7445.am2022-1863
https://doi.org/10.1158/1538-7445.am2022-1863
Autor:
Chunting Ye, Mingshan Cheng, Michael A. Brehm, James G. Keck, Jens Rueter, Lenny Shultz, Dale L. Greiner
Publikováno v:
Journal of Clinical Oncology. 37:2612-2612
2612 Background: Although antibodies and CART cells therapies have been successfully used for cancer therapy, they can have lethal adverse effects such as cytokine release syndrome (CRS). The animal models and in vitro human PBMC assays presently in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9ec925531d147627a1eea49807109f4c
https://doi.org/10.1200/jco.2019.37.15_suppl.2612
https://doi.org/10.1200/jco.2019.37.15_suppl.2612
Publikováno v:
Clinical Cancer Research. 22:IA13-IA13
The Patient Derived Xenograft (PDX) Program at The Jackson Laboratory have as its focus, the development of quality surrogates of primary human tumors for the research community, the construction and optimization of murine hosts for human tumor xenog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04d3f51e2d3e8275cff0be68d8c622b0
https://doi.org/10.1158/1557-3265.pdx16-ia13
https://doi.org/10.1158/1557-3265.pdx16-ia13
Autor:
Regina F Gandour-Edwards, Clifford G. Tepper, Xing Yi Woo, Lenny Shultz, Tianhong Li, Joshy George, Carol J. Bult, Joel H. Graber, Yan Yang, Philip C. Mack, Hyun-Soo Kim, Jeffrey H. Chuang, Primo N. Lara, R. Krishna Murthy Karuturi, Edison T. Liu, James L. Keck, Rebekah A. Burich, David R. Gandara, Ralph de Vere White, Susan D. Airhart
Publikováno v:
Journal of Clinical Oncology. 32:e22151-e22151
e22151 Background: To address the demand for new pre-clinical models,The Jackson Laboratory (JAX), in collaboration with founding member UCDCC and 24 other medical centers, has engrafted primary an...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6614191f6a725bf33d9c0f70fc8e8a17
https://doi.org/10.1200/jco.2014.32.15_suppl.e22151
https://doi.org/10.1200/jco.2014.32.15_suppl.e22151
Autor:
Enzo Medico, Stefano Pileri, Rodolfo Machiorlatti, Marco Chilosi, Antonella Barreca, Fabrizio Tabbò, Domenico Novero, Pier Paolo Piccaluga, Michela Boi, Alberto Zamò, Raul Rabadan, Maria Todaro, Mangeng Cheng, Cristina Abele, Francesco Abate, Enrico Tiacci, Roberto Piva, Giorgio Inghirami, Lenny Shultz, Bruce Ruggeri, Indira Landra, Maurilio Ponzoni, Katia Messana, Brunangelo Falini, Francesco Bertoni
Publikováno v:
Cancer Research. 73:3853-3853
Anaplastic large cell lymphoma (ALCL) is a subtype of peripheral T-cell lymphoma that includes two entities ALK+ and ALK- ALCL based on chromosomal translocations of the anaplastic lymphoma kinase (ALK). ALK- ALCL have very poor clinical outcome with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f8c18276811197dd21829ff80b879535
https://doi.org/10.1158/1538-7445.am2013-3853
https://doi.org/10.1158/1538-7445.am2013-3853
Autor:
Lenny Shultz, Tessa L. Holyoake, Adam C. Strauss, Yin Wei Ho, Bin Zhang, Ravi Bhatia, David S. Snyder, Claudia S. Huettner, Su Chu
Publikováno v:
Blood. 114:190-190
Abstract 190 The BCR-ABL tyrosine kinase inhibitor imatinib mesylate (IM) is highly effective in inducing remissions and improving survival in CML patients but fails to eliminate leukemia stem cells, which remain a potential source of relapse. Quiesc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::473e2f904e06d4c53f3dccb1bc7cc273
https://doi.org/10.1182/blood.v114.22.190.190
https://doi.org/10.1182/blood.v114.22.190.190